Addition of Ibrutinib to Chemoimmunotherapy Continues to Benefit Overall Survival

首页> 外文期刊>Clinical advances in hematology & oncology: H&O >Addition of Ibrutinib to Chemoimmunotherapy Continues to Benefit Overall Survival

【24h】

Addition of Ibrutinib to Chemoimmunotherapy Continues to Benefit Overall Survival

机译：添加Ibrutinib以培养的化学疗法继续促进整体生存

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The addition of ibrutinib to chemoimmunotherapy with bendamustine (Treanda/Bendeka; Teva) plus rituximab continues to benefit overall survival (OS) in patients with relapsed or refractory CLL or small lymphocytic leukemia (SLL), according to 5-year results from the HELIOS study. This finding is consistent with the 3-year results from the trial.

机译：None

著录项

来源
《Clinical advances in hematology & oncology: H&O》 |2020年第10期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage Ⅰ diffuse large B-cell lymphoma [J] . Bo Jia, Yuankai Shi, Suyi Kang, 中国癌症研究（英文版） . 2015,第005期
2. Sharing Benefits--China will continue to open up its market through Shanghai expo [J] . Zhang Jiuqin 北京周报：英文版 . 2020,第045期
3. Methodology of Care Humanitude Implementation at an Integrated Continuing Care Unit: Benefits for the Individuals Receiving Care [J] . Liliana Henriques, Marília Dourado, Rosa Melo, 护理学期刊（英文） . 2020,第010期
4. Short-Term and Continuing Stresses Differentially Interplay with Multiple Hormones to Regulate Plant Survival and Growth [J] . Cangjing Yang, Jingjing Liu, Xinran Dong, 分子植物（英文版） . 2014,第005期
5. Ibrutinib improves survival for relapsed or refractory chronic lymphocytic leukemia (CLL) after first-line chemoimmunotherapy: population-based outcomes from 677 patients treated in British Columbia (BC) [J] . Gerrie Alina S., VanderVeer Elysha, Huang Steven, Leukemia and lymphoma . 2020,第S1期

机译：伊布洛替尼改善了一线化疗后的复发或难治性慢性淋巴细胞白血病（CLL）的存活：从不列颠哥伦比亚省（BC）治疗的677名患者的群体基于677名患者的结果
6. Response and survival benefit with chemoimmunotherapy in Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma [J] . Beltran Brady E., Qui?ones Pilar, Morales Domingo, Hematological oncology . 2018,第1期

机译：Epstein-Barr病毒阳性弥漫性大B细胞淋巴瘤中的响应和生存效果
7. Response and survival benefit with chemoimmunotherapy in Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma [J] . Beltran Brady E., Qui?ones Pilar, Morales Domingo, Hematological oncology . 2018,第1期

机译：Epstein-Barr病毒阳性弥漫性大B细胞淋巴瘤中的响应和生存效果
8. Advanced Methods to Mitigate Bromate Formation in Ozonated Groundwater: Relative Benefits of the Ammonia-Chlorine Process, Acid Addition, Chlorine Dioxide Addition, NOM Precursor Removal and Their Combinations [C] . Jonathan P. Loveland, Edward G. Means III World Congress on Ozone and Ultraviolet Technologies . 2007

机译：在臭氧处理地下水中减轻溴酸盐形成的先进方法：氨氯的相对益处，酸加成，二氧化氯添加，NOM前体移除及其组合
9. Self-directed continuing learning, employment benefit packages, and the motivations of unionized nurses to engage in continuous education. [D] . Esposito, Carol Lynn. 2012

机译：自我指导的继续学习，就业福利计划以及工会护士参与持续教育的动机。
10. Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma [O] . Bo Jia, Yuankai Shi, Suyi Kang, 2015

机译：I期弥漫性大B细胞淋巴瘤患者与单独使用CHOP相比添加利妥昔单抗与生存获益无关
11. No survival benefit in follicular lymphoma with first-line intensive chemoimmunotherapy [O] . 2008

机译：毛囊淋巴瘤没有生存益处，具有一线密集型化疗疗法
12. Does Glucagon Improve Survival in a Porcine (Sus Scrofa) of Adult Asphyxial Cardiac Arrest in Addition to Standard Epinephrine Therapy [R] . Thompson, A., Williams, J., Bebarta, V., 2012

机译：除标准肾上腺素治疗外，胰高血糖素还能改善成人窒息性心脏骤停的猪（sus scrofa）的存活率

Addition of Ibrutinib to Chemoimmunotherapy Continues to Benefit Overall Survival

摘要

著录项

相似文献

相关主题

期刊订阅